Monopar Therapeutics(MNPR) - 2025 Q4 - Annual Report

FORM 10-K Table of Contents | UNITED STATES | | | --- | --- | | SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | | | (Mark One) | | | Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | ☒ | | For the Fiscal Year Ended December 31, 2025 | | | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | ☐ | | For the transition period from_______________ to ________________ | | | Commission File Number: 001-39070 | | | ...